Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 known ✓ | P23921 | 1/20 | 0.39 |
| ▸ | S1PR2 known ✓ | O95136 | 2/20 | 0.33 |
| ▸ | S1PR1 known ✓ | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 known ✓ | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR5 known ✓ | Q9H228 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27908684 | 1.00 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL446666 | 1.00 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL27686644 | 1.00 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL20699446 | 0.99 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL18148989 | 0.99 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL20564397 | 0.94 | SLC6A5 (0.38) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL403392 | 0.94 | SLC6A5 (0.38) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| Hydrochloric Acid SCHEMBL403391 | 0.94 | SLC6A5 (0.38) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL25364547 | 0.92 | EPHX2 (0.39) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL3975666 | 0.92 | EPHX2 (0.39) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3500670-B1 | METHOD FOR SELECTING TARGET SEQUENCES FOR GUIDE RNA OF CRISPR SYSTEMS | BROAD INST INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11999767-B2 | Target recognition motifs and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240124860-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-18 | — | — | US | disclosed |
| US-20240076651-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-07 | — | — | US | disclosed |
| US-20210093667-A1 | CRISPR/CAS-ADENINE DEAMINASE BASED COMPOSITIONS, SYSTEMS, AND METHODS FOR TARGETED NUCLEIC ACID EDITING | THE BROAD INSTITUTE, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200283743-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | THE BROAD INSTITUTE, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200255861-A1 | CRISPR CPF1 DIRECT REPEAT VARIANTS | THE BROAD INSTITUTE, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200248169-A1 | CRISPR/CAS-CYTIDINE DEAMINASE BASED COMPOSITIONS, SYSTEMS, AND METHODS FOR TARGETED NUCLEIC ACID EDITING | THE BROAD INSTITUTE, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| CN-111328290-A | CRISPR/CAS-adenine deaminase-based compositions, systems, and methods for targeted nucleic acid editing | 博德研究所 | 2020-06-23 | — | — | CN | disclosed |
| WO-2006069782-A9 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090074852-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS AG (DE) | 2009-03-19 | — | — | US | disclosed |
| EP-2007356-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | Silence Therapeutics AG (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | SILENCE THERAPEUTICS AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2007121947-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | SILENCE THERAPEUTICS AG. (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1830888-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | Silence Therapeutics AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| CN-1968714-A | Lipid, lipid complex and application thereof | ATUGEN AG (DE) | 2007-05-23 | — | — | CN | disclosed |
| EP-1771206-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | atugen AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006069782-A2 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG. (DE) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074852-A1 | LIPOPLEX FORMULATIONS FOR SPECIFIC DELIVERY TO VASCULAR ENDOTHELIUM | LIPG, LIPA, PHOSPHO1 | RRM1 1989/4885S1PR2 17/4885S1PR1 25/4885 |
| US-20210093667-A1 | CRISPR/CAS-ADENINE DEAMINASE BASED COMPOSITIONS, SYSTEMS, AND METHODS FOR TARGETED NUCLEIC ACID EDITING | ADA, ADAR, APOBEC3C | RRM1 235/4885S1PR2 4065/4885S1PR1 3899/4885 |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | KLRK1, CD47, FCGR3B | RRM1 2884/4885S1PR2 1126/4885S1PR1 683/4885 |
| US-11999767-B2 | Target recognition motifs and uses thereof | MICA, CNBP, MARCKS | RRM1 1528/4885S1PR2 3902/4885S1PR1 3641/4885 |
| US-20240076651-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | ADA, APOBEC3A, CDA | RRM1 445/4885S1PR2 3638/4885S1PR1 3626/4885 |
| US-20080274116-A1 | Lipids, Lipid Complexes and Use Thereof | MGLL, LIPA, SGMS1 | RRM1 2638/4885S1PR2 128/4885S1PR1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.